The FDA on Monday approved Wilserdly, also known as giredestrant, a new breast cancer medicine from Roche, clearing the way for a launch that the Swiss drugmaker has said could become its best-selling product ever.
The decision was one of the most closely watched regulatory milestones for Roche. It also strengthens the company’s position in breast cancer, where it has a long legacy through Genentech’s Herceptin but has more recently lost ground in oncology to rival pharmaceutical companies.
The approval specifically covers patients with HR-positive, HER2-negative advanced breast cancer whose tumors carry an ESR1 mutation, a sign that the cancer is developing resistance to standard treatments. In the evERA trial, giredestrant—an oral selective estrogen receptor degrader, or SERD—extended the time before patients’ tumors progressed.
Also Read
- How Effective Is Stock Epinephrine in School-Based Anaphylaxis?
- Vitamin B12 Reverses Developmental Defects in a Worm Model of Verheij Syndrome
- Long-Term Study Links Daytime Napping Patterns to Mortality Risk in Older Adults
- Duet Raises $15M Series A to Expand Nurse Practitioner-Owned Primary Care Network


